SPNS1 variants cause multiorgan disease and implicate lysophospholipid transport as critical for mTOR-regulated lipid homeostasis
Authors:
- Menglan HeMHMenglan He
- Mei DingMDMei Ding
- Michaela ChocholouskovaMCMichaela Chocholouskova
- Cheen Fei ChinCCCheen Fei Chin
- Martin EngvallMEMartin Engvall
- Helena MalmgrenHMHelena Malmgren
- Matias WagnerMWMatias Wagner
- Marlen C. LaufferMLMarlen C. Lauffer
- Jacob HeisingerJHJacob Heisinger
- May Christine V. MalicdanMMMay Christine V. Malicdan
- Madeleine DurbeejMDMadeleine Durbeej
Open Access
- 3 July 2025
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (17)
Abstract
SPNS1 is a lysosomal transporter that mediates the salvage of lysoglycerophospholipids, the degradative products of lysosomal phospholipid catabolism. However, an understanding of the role of lysolipid transport and salvage in regulating cellular lipid homeostasis and in disease is lacking. Here, we identified members of 2 families with biallelic SPNS1 loss-of-function variants, who presented primarily with progressive liver and striated muscle injury. Patients’ fibroblasts accumulated lysophospholipids including lysoplasmalogens and cholesterol in lysosomes with reduced cellular plasmalogens. Notably, SPNS1 deficiency resulted in reduced biogenesis of cytosolic lipid droplets containing triglycerides and cholesteryl esters. Mechanistically, we found that lysophospholipids transported by SPNS1 into the cytosol quantitatively contributed to triglyceride synthesis, whereas lysosomal buildup of lyso-ether-phospholipid inhibited lysosomal cholesterol egress, effects that were enhanced with inhibition of mTOR. These findings support a gene-disease association and reveal connectivity between lysosomal transport of lysophospholipids and storage of reserve cellular energy as triglycerides and the regulation of cholesterol homeostasis, processes that become important under nutrient limitation.Keywords
Funding Information
- Ministry of Health Singapore (MOH-000217,MOH-001206)
- Ministry of Education Singapore (MOE-T2EP30220-0001,MOE2019-T2-1-031)
- Goh Cardiovascular Research Award (Duke-NUS-GCR/2025/0044)
- SingHealth Duke-NUS Genomic Medicine Centre Seed Grant (SDDC/FY2023/EX/79-A117)
- Ministry of Health Singapore (MOH-001234)
- Swedish Childhood Cancer Fund (PR2022-0027)
- Vetenskapsrådet (2023-06393))
- Vetenskapsrådet ((2021-02860)
- Deutsche Forschungsgemeinschaft (521414448)
This publication has 59 references indexed in Scilit:
- Deficiency in ethanolamine plasmalogen leads to altered cholesterol transportJournal of Lipid Research, 2003
- Impaired membrane traffic in defective ether lipid biosynthesisHuman Molecular Genetics, 2001
- Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether.1999
- Plasmalogen Phospholipids Are Involved in HDL-Mediated Cholesterol Efflux: Insights from Investigations with Plasmalogen-Deficient CellsBiochemical and Biophysical Research Communications, 1998
- Murine Model of Niemann-Pick C Disease: Mutation in a Cholesterol Homeostasis GeneScience, 1997
- Niemann-Pick C1 Disease Gene: Homology to Mediators of Cholesterol HomeostasisScience, 1997
- The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription FactorCell, 1997
- Role of the plasma membrane in cholesterol esterification in rat hepatoma cellsJournal of Biological Chemistry, 1993
- Rapid isolation of neuroblastoma plasma membranes on Percoll gradients. Characterization and lipid compositionBiochimica et Biophysica Acta (BBA) - Biomembranes, 1985
- Lysophosphatidylcholine-cholesterol complex.Journal of Biological Chemistry, 1982